Research
Hormonal
Semaglutide increases the proportion of patients achieving significant weight loss thresholds (>5%, >10%, >15%, and >20%) compared to control groups.
Semaglutide significantly increases the likelihood of achieving major weight loss milestones (5%, 10%, 15%, 20%) compared to placebo or other treatments.
GoodSupportsHIGH confidence
the proportion of patients who lost > 5%, 10%, 15%, and 20% of their overall body weight, respectively (RR = 3.19, 95% CI [1.89, 5.36], P < 0.001), (RR = 4.74, 95% CI [2.78, 8.11], P < 0.001), (RR = 6.17, 95% CI [3.88, 9.82], P < 0.001), and (RR = 9.14, 95% CI [6.05, 13.80], P < 0.001) were also superior to the control group.
Why this rating
Based on meta-analysis of RCTs.
Source
Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis
Yang Liu et al. · Journal of Research in Medical Sciences · 2024
DOI 10.4103/jrms.jrms_693_23
Meta-analysis · 15 studiesCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (GLP-1 receptor agonist) significantly reduces body weight, BMI, and waist circumference in overweight or obese adults, with or without type 2 diabetes, compared to placebo or other glucose-lowering medications.Good
- Semaglutide significantly improves glycemic control (HbA1c and fasting blood glucose) and systolic blood pressure in overweight or obese adults, with or without type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →